Entry verification

You are about to enter a research catalogue.

Compounds shown on this site are sold strictly for laboratory and research use. They are not licensed medicines and are not intended for human or veterinary consumption. UK 18+ verification is required to enter.

Date of birth

Date of birth (day, month, year)
I do not qualify · leave the site

MHRA · ASA · ICO · UK GDPR aware

Amber-glass lyophilised vial of Tirzepatide with white flip-cap and Optimal Lab cream-stripe label
fig. tirzepatide · 30mg · LYOPHILISEDJanoshik-tested
Metabolic Pathways

Tirzepatide

GIP/GLP-1 dual receptor agonist. Phase 3 SURMOUNT-1 trial published in NEJM 2022.[1]

Variants
Select variant size
Quantity
1

PayPal or cash on collection · UK 18+ verification at dispatch · For laboratory research use only

HPLC chromatogram

Reverse-phase trace

Single peak at the expected retention time. Area % integration shown on every lot record. Per-lot chromatogram available on request from our supplier, Janoshik.

Reconstitution

Math, not dosing

For 30mg vial + 2 mL BAC water → concentration calculation on the dedicated calculator page. We provide research procedure only.

Selected research · Tirzepatide

  1. [1]Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine.SURMOUNT-1 phase 3 trial of tirzepatide in adults with obesity. Mean weight reduction 22.5% at 72 weeks.PMID 35658024 →

All references describe published research on the compound. They do not constitute clinical guidance or imply therapeutic benefit to any individual purchaser. For laboratory research use only.